Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg); dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 3350; silicified microcrystalline cellulose; povidone; sodium starch glycollate type a; polyvinyl alcohol; microcrystalline cellulose; magnesium stearate; lactose monohydrate; iron oxide yellow; croscarmellose sodium; iron oxide red; mannitol; purified talc; titanium dioxide; sodium stearylfumarate; polysorbate 20 - juluca (dolutegravir/rilpivirine) is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fostemsavir trometamol, quantity: 724.56 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hyprolose; hypromellose; magnesium stearate; titanium dioxide; purified talc; iron oxide red; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - rukobia is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant human immunodeficiency virus-1 (hiv-1) infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - cabotegravir, quantity: 30 mg (equivalent: cabotegravir sodium, qty mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; macrogol 3350 - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) and have no known or suspected resistance to either cabotegravir or rilpivirine (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials) for: ? oral lead in to assess tolerability of cabotegravir prior to administration of cabotegravir prolonged-release suspension for injection plus rilpivirine prolonged-release suspension for injection. ? oral therapy for adults who will miss planned dosing with cabotegravir prolonged-release suspension for injection.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - dolutegravir sodium, quantity: 5.26 mg (equivalent: dolutegravir, qty 5 mg) - tablet, dispersible - excipient ingredients: sodium starch glycollate; mannitol; microcrystalline cellulose; povidone; purified water; silicified microcrystalline cellulose; crospovidone; calcium sulfate dihydrate; sucralose; sodium stearylfumarate; hypromellose; macrogol 400; titanium dioxide; flavour - tivicay and tivicay pd are indicated for the treatment of human immunodeficiency virus (hiv) infection in combination with other antiretroviral agents in adults and children of at least 4 weeks in age or older and weighing 3 kg or more (see section 4.4 special warnings and precautions for use, dual regimens).

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate; lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine; lamivudine; abacavir sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine; lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - trelavue is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in trelavue.